With an emphasis on the ability of patients and caregivers to adapt to challenges, the International Myeloma Foundation (IMF) is seeking to raise awareness…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them…
The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc), in combination with Pomalyst (pomalidomide) and dexamethasone,…
One of the most common genomic defects in multiple myeloma patients is the loss of one copy of chromosome 13, and researchers now suggest that…
Cellectar Biosciences’ lead candidate CLR 131 safely and effectively prevents disease progression or reduces tumors in people with hard-to-treat multiple myeloma, according…
A new CAR T-cell therapy  for people with multiple myeloma has been successfully created and tested in…
